Quick Answer
Inmune Bio, Inc. reported Shares Outstanding of 26.59 million shares for fiscal year 2025.
Inmune Bio, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 26.59M | +19.3% |
| 2024 | 22.28M | +24.1% |
| 2023 | 17.95M | +0.0% |
| 2022 | 17.95M | +0.6% |
| 2021 | 17.84M | +32.4% |
| 2020 | 13.48M | +25.2% |
| 2019 | 10.77M | +23.5% |
| 2018 | 8.72M | +4.8% |
| 2017 | 8.32M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 26.59M | +19.9% | +0.0% |
| June 30, 2025 | 26.59M | +34.9% | +15.9% |
| March 31, 2025 | 22.93M | +27.7% | +2.9% |
| December 31, 2024 | 22.28M | +24.1% | +0.5% |
| September 30, 2024 | 22.17M | +23.6% | +12.5% |
| June 30, 2024 | 19.71M | +9.8% | +9.8% |
| March 31, 2024 | 17.95M | +0.0% | +0.0% |
| December 31, 2023 | 17.95M | +0.0% | +0.0% |
- Inmune Bio, Inc. showed an increase of +19.3% in Shares Outstanding compared to the prior fiscal year.
- Over the 2017–2025 period, Inmune Bio, Inc.’s shares outstanding has grown by 219.6% (from 8.32 million shares to 26.59 million shares).
- The most recent figure is from Inmune Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: